42 participants
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-20
- Start Date:
- 2026-05-18
- Completion:
- 2030-04-30
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Invasive Breast Carcinoma
- Localized Estrogen Receptor-Positive Breast Carcinoma
- Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
Interventions
- DRUG
- PROCEDURE
- OTHER
No Results Yet